MorphoSys AG (Frankfurt Stock Exchange: MOR; Prime Standard Segment) announced today that an undisclosed partner has filed all necessary documentation to initiate a Phase 1 clinical trial with a HuCAL-derived fully human antibody in the therapeutic area of oncology. This achievement marks the third fully human antibody developed with MorphoSys's core technology within its partnerships to enter human clinical trials and triggers a clinical milestone payment to MorphoSys.

 

'This is an exciting program for the treatment of cancer and we are therefore delighted to see the program move into human clinical trials,' commented Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG. 'This latest addition to the roster of HuCAL antibodies in the clinic underlines the fact that our therapeutic pipeline is growing and maturing. The strength of this pipeline is a core asset of MorphoSys that will be a key driver of the company's future growth.'